Medicaid is doing a novel payment system for the new, promising and expensive sickle cell treatment. It may become a model ...
Under the agreement, participating states will receive “discounts and rebates” from the drugmakers if the treatments don’t ...
Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies 90% (9 of 10) of patients were able to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results